Dyslipidemia News and Research RSS Feed - Dyslipidemia News and Research

Dyslipidemia is a disruption in the amount of lipids in the blood.
Study explains gender differences in the impact of OSA on cardiovascular disease, mortality

Study explains gender differences in the impact of OSA on cardiovascular disease, mortality

A new study from researchers in Japan indicates that obstructive sleep apnea is independently associated with visceral (abdominal) fat accumulation only in men, perhaps explaining gender differences in the impact of OSA on cardiovascular disease and mortality. [More]
AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes. [More]
FDA approves Mylan's ANDA for Fenofibrate Tablets

FDA approves Mylan's ANDA for Fenofibrate Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. [More]
Spanish researchers link job-related stress to dyslipidemia

Spanish researchers link job-related stress to dyslipidemia

Spanish researchers have studied how job stress affects cardiovascular health. The results, published in the 'Scandinavian Journal of Public Health', link this situation to dyslipidemia, a disorder that alters the levels of lipids and lipoproteins in the blood. [More]
Hypertensive patients may need firm dietary advice

Hypertensive patients may need firm dietary advice

People who have dyslipidemia or are overweight adopt healthier diets than those without, whereas patients with hypertension persist with some unhealthy eating patterns, study results show. [More]

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors. [More]
Obesity epidemic in the Asia Pacific region: an interview with Prof Drexel, European Society of Cardiology

Obesity epidemic in the Asia Pacific region: an interview with Prof Drexel, European Society of Cardiology

The prevalence of obesity is about 20 % in Australia, 17 % in Japan, but only 3 – 4 % in China. Thus, Asia Pacific is a very heterogeneous region. [More]
Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients. [More]
Cardiovascular disease risk in women higher than you think

Cardiovascular disease risk in women higher than you think

In conjunction with International Women's Day, the European Cardiology Society reminds women that they may be at a greater risk for cardiovascular disease (CVD) than they think. [More]
Cholesterol levels seem to fluctuate significantly with turning seasons

Cholesterol levels seem to fluctuate significantly with turning seasons

Cholesterol levels seem to fluctuate significantly with the turning seasons, which may leave some people with borderline high cholesterol at greater cardiovascular risk during the winter months, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia. [More]
CT angiography uncovers cardiovascular disease risk

CT angiography uncovers cardiovascular disease risk

Computed tomography angiography can warn of the likelihood for major adverse cardiovascular events in patients suspected of having coronary artery disease in the absence of medically modifiable risk factors, research shows. [More]
Researchers discover miR-27b that regulates lipid levels in the blood

Researchers discover miR-27b that regulates lipid levels in the blood

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease. [More]

Liver gene found to regulate cholesterol and fat blood levels

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia—abnormal blood cholesterol levels that can contribute to heart disease. [More]
Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology [More]

Increasing age, male sex and adiposity risk factors for metabolic syndrome in children

Metabolic syndrome is more likely to affect children who are obese than overweight or non-overweight and who have other characteristics associated with the disorder, such as high blood pressure or insulin resistance. A new comprehensive and systematic review of the medical literature on metabolic syndrome in children that probed deeper to evaluate the risk associated with gender, ethnicity, and geography was published in Metabolic Syndrome and Related Disorders, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed. [More]
Shoulder complaint linked to diabetes diagnosis

Shoulder complaint linked to diabetes diagnosis

Study findings confirm suspicions that patients with diabetes have an increased risk for adhesive capsulitis of the shoulder. [More]
Toxin-induced insulin resistance combated in mice

Toxin-induced insulin resistance combated in mice

French researchers have found that a protein-bound uremic toxin, p-cresyl sulfate, contributes to the development of insulin resistance in mice, providing a new potential therapeutic target for treating chronic kidney disease, they say. [More]

Study on prevalence of coronary atherosclerosis among U.S. soldiers

Among deployed U.S. service members who died of combat or unintentional injuries between 2001-2011 and underwent autopsies, the prevalence of coronary atherosclerosis was 8.5 percent, with factors associated with a higher prevalence of the disease including older age, lower educational level and prior diagnoses of dyslipidemia, hypertension, and obesity, according to a study in the December 26 issue of JAMA. [More]